Search details
1.
Lung Oligometastasis of Breast Cancer: Prospective Cohort Study of Treatment Strategies (SBP-06).
Acta Med Okayama
; 78(1): 15-20, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38419310
2.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat
; 201(3): 409-415, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37480384
3.
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Breast Cancer Res Treat
; 199(2): 231-241, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36947277
4.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 53(3): 203-211, 2023 Mar 07.
Article
in English
| MEDLINE | ID: mdl-36484305
5.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
BMC Med
; 20(1): 136, 2022 04 25.
Article
in English
| MEDLINE | ID: mdl-35462552
6.
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
BMC Cancer
; 22(1): 31, 2022 Jan 03.
Article
in English
| MEDLINE | ID: mdl-34980019
7.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 52(6): 545-553, 2022 May 31.
Article
in English
| MEDLINE | ID: mdl-35296894
8.
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(4): 499-511, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33676601
9.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Breast Cancer Res Treat
; 190(3): 425-434, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34554370
10.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Breast Cancer Res Treat
; 188(1): 117-131, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33763789
11.
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Breast Cancer Res Treat
; 185(1): 125-134, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32920732
12.
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
BMC Cancer
; 21(1): 795, 2021 Jul 09.
Article
in English
| MEDLINE | ID: mdl-34238257
13.
Risk factors of local recurrence following implant-based breast reconstruction in breast cancer patients.
BMC Womens Health
; 21(1): 147, 2021 04 10.
Article
in English
| MEDLINE | ID: mdl-33838670
14.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 26(7): 1229-1236, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33891194
15.
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
Int J Clin Oncol
; 26(1): 1-17, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33161452
16.
Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer.
Acta Med Okayama
; 75(3): 357-362, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-34176940
17.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
N Engl J Med
; 376(22): 2147-2159, 2017 06 01.
Article
in English
| MEDLINE | ID: mdl-28564564
18.
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Breast Cancer Res Treat
; 180(1): 135-146, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31953696
19.
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Breast Cancer Res Treat
; 180(3): 715-724, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-32170634
20.
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Jpn J Clin Oncol
; 50(1): 3-11, 2020 Jan 24.
Article
in English
| MEDLINE | ID: mdl-31821506